. Author manuscript; available in PMC: 2023 Oct 18.

Published in final edited form as: Eur J Med Chem. 2022 Nov 11;245(Pt 2):114916. doi: 10.1016/j.ejmech.2022.114916

Table 4.

Activity of 26a against a panel of Mtb mutants and against MDR clinical isolates.

Strain	MIC₉₀^a (μg/mL)
	26a	Isoniazid

H37Rv	0.5	0.025
53.3 (Rv2466c, W28S)[55]	0.5	0.025
53.8 (Rv0579, L240V)[57]	0.5	0.025
NTB1 (dprE1, G387S)[54]	0.5	0.025
DR1 (mmpl3, V681I)[51]	0.5	0.025
Ty1 (Rv3405c, c190t)[56]	0.5	0.025
88.1 (coaA, Q207R)[52]	0.5	0.025
88.7 (pyrG, V186G)[53]	0.5	0.025
81.10 (ethA, Δ1109–37)[53]	0.5	0.025
IC1 (res. to STR, INH, RIF, EMB, ETH)[58]	0.5	>0.2
IC2 (res. to STR, INH, RIF, EMB, PYR, ETH, CM)[58]	0.5	>0.2

Minimum Inhibitory Concentration, determined by micro-broth dilution method.